Marchand Lucas S, Sprague Sheila, O'Hara Nathan N, Li Chuan Silvia, O'Toole Robert V, Joshi Manjari, Viskontas Darius, Romeo Nicholas, Hymes Robert A, Obremskey William T, Higgins Thomas F, Potter Gorden D, Bergin Patrick F, Gage Mark, Gary Joshua L, Bhandari Mohit, Slobogean Gerard P
Department of Orthopaedic Surgery, University of Utah, Salt Lake City, UT.
Department of Surgery, McMaster University, Hamilton, ON, Canada.
OTA Int. 2023 Feb 21;6(1):e223. doi: 10.1097/OI9.0000000000000223. eCollection 2023 Mar.
Surgical site infections in orthopaedic trauma are a significant problem with meaningful patient and health care system-level consequences. Direct application of antibiotics to the surgical field has many potential benefits in reducing surgical site infections. However, to date, the data regarding the local administration of antibiotics have been mixed. This study reports on the variability of prophylactic vancomycin powder use in orthopaedic trauma cases across 28 centers.
Intrawound topical antibiotic powder use was prospectively collected within three multicenter fracture fixation trials. Fracture location, Gustilo classification, recruiting center, and surgeon information were collected. Differences in practice patterns across recruiting center and injury characteristics were tested using chi-square statistic and logistic regression. Additional stratified analyses by recruiting center and individual surgeon were performed.
A total of 4941 fractures were treated, and vancomycin powder was used in 1547 patients (31%) overall. Local administration of vancomycin powder was more frequent in open fractures 38.8% (738/1901) compared with closed fractures 26.6% (809/3040) ( < 0.001). However, the severity of the open fracture type did not affect the rate at which vancomycin powder was used ( = 0.11). Vancomycin powder use varied substantially across the clinical sites ( < 0.001). At the surgeon level, 75.0% used vancomycin powder in less than one-quarter of their cases.
Prophylactic intrawound vancomycin powder remains controversial with varied support throughout the literature. This study demonstrates wide variability in its use across institutions, fracture types, and surgeons. This study highlights the opportunity for increased practice standardization for infection prophylaxis interventions.
Prognostic-III.
骨科创伤手术部位感染是一个严重问题,会给患者和医疗系统带来重大影响。在手术区域直接应用抗生素对于减少手术部位感染有诸多潜在益处。然而,迄今为止,关于局部应用抗生素的数据并不一致。本研究报告了28个中心在骨科创伤病例中预防性使用万古霉素粉末的差异情况。
在三项多中心骨折固定试验中前瞻性收集伤口内局部应用抗生素粉末的情况。收集骨折部位、 Gustilo分级、招募中心和外科医生信息。使用卡方统计量和逻辑回归检验招募中心和损伤特征在实践模式上的差异。还按招募中心和个体外科医生进行了额外的分层分析。
共治疗4941例骨折,总体上1547例患者(31%)使用了万古霉素粉末。开放性骨折中局部应用万古霉素粉末更为频繁,为38.8%(738/1901),而闭合性骨折为26.6%(809/3040)(P<0.001)。然而,开放性骨折类型的严重程度并未影响万古霉素粉末的使用比例(P = 0.11)。万古霉素粉末的使用在各临床地点差异很大(P<0.001)。在外科医生层面,75.0%的医生在不到四分之一的病例中使用万古霉素粉末。
预防性伤口内应用万古霉素粉末在整个文献中仍存在争议,支持程度不一。本研究表明其在不同机构、骨折类型和外科医生中的使用差异很大。本研究强调了提高感染预防干预措施实践标准化的机会。
预后性III级。